BACKGROUND: The association between buprenorphine taper duration and treatment outcomes is not well understood. This review evaluated whether duration of outpatient buprenorphine taper is significantly associated with treatment outcomes. METHODS: Studies that were published in peer-reviewed journals, administered buprenorphine as an outpatient taper to opioid-dependent participants, and provided data on at least one of three primary treatment outcome measures (opioid abstinence, retention, peak withdrawal severity) were reviewed. Primary treatment outcomes were evaluated as a function of taper duration using hierarchical linear regressions with pre-taper maintenance duration as a cofactor. RESULTS: Twenty-eight studies were reviewed. Taper duration significantly predicted percent of opioid-negative samples provided during treatment, however pre-taper maintenance period predicted percent participants abstinent on the final day of treatment. High rates of relapse were reported. No significant association between taper duration and retention in treatment or peak withdrawal severity was observed. CONCLUSION: The data reviewed here suggest taper duration is associated with opioid abstinence achieved during detoxification but not with other markers of treatment outcome. The reviewed studies varied widely on several parameters (e.g., frequency of urinalysis testing, provision of ancillary medications) that may influence treatment outcome and thus could have interfered with the ability to identify relationships between taper duration and outcomes. Future studies evaluating opioid detoxification should utilize rigorous experimental methods and report a wider range of outcome measures in order to help advance our understanding of the association between taper duration and treatment outcomes.
BACKGROUND: The association between buprenorphine taper duration and treatment outcomes is not well understood. This review evaluated whether duration of outpatientbuprenorphine taper is significantly associated with treatment outcomes. METHODS: Studies that were published in peer-reviewed journals, administered buprenorphine as an outpatient taper to opioid-dependent participants, and provided data on at least one of three primary treatment outcome measures (opioid abstinence, retention, peak withdrawal severity) were reviewed. Primary treatment outcomes were evaluated as a function of taper duration using hierarchical linear regressions with pre-taper maintenance duration as a cofactor. RESULTS: Twenty-eight studies were reviewed. Taper duration significantly predicted percent of opioid-negative samples provided during treatment, however pre-taper maintenance period predicted percent participants abstinent on the final day of treatment. High rates of relapse were reported. No significant association between taper duration and retention in treatment or peak withdrawal severity was observed. CONCLUSION: The data reviewed here suggest taper duration is associated with opioid abstinence achieved during detoxification but not with other markers of treatment outcome. The reviewed studies varied widely on several parameters (e.g., frequency of urinalysis testing, provision of ancillary medications) that may influence treatment outcome and thus could have interfered with the ability to identify relationships between taper duration and outcomes. Future studies evaluating opioid detoxification should utilize rigorous experimental methods and report a wider range of outcome measures in order to help advance our understanding of the association between taper duration and treatment outcomes.
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: Jason White; James Bell; John B Saunders; Paul Williamson; Maria Makowska; Aaron Farquharson; Katherine L Beebe Journal: Drug Alcohol Depend Date: 2009-04-28 Impact factor: 4.492
Authors: Courtney L Breen; Simon J Harris; Nicholas Lintzeris; Richard P Mattick; Lynn Hawken; James Bell; Alison J Ritter; Michael Lenné; Elizabeth Mendoza Journal: Drug Alcohol Depend Date: 2003-07-20 Impact factor: 4.492
Authors: Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody Journal: Am J Drug Alcohol Abuse Date: 2012-03-12 Impact factor: 3.829
Authors: Lisa A Marsch; Sarah K Moore; Jacob T Borodovsky; Ramon Solhkhah; Gary J Badger; Shelby Semino; Kate Jarrett; Kathleen DiGangi Condon; Kate Rossettie; Phillip Vincent; Neda Hajizadeh; Elizabeth Ducat Journal: Addiction Date: 2016-04-21 Impact factor: 6.526
Authors: Angela L Stotts; Charles Green; Akihiko Masuda; John Grabowski; Kelly Wilson; Thomas F Northrup; F Gerard Moeller; Joy M Schmitz Journal: Drug Alcohol Depend Date: 2012-03-15 Impact factor: 4.492
Authors: Brantley P Jarvis; August F Holtyn; Meredith S Berry; Shrinidhi Subramaniam; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman Journal: J Subst Abuse Treat Date: 2017-04-20
Authors: Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Miller; Paul A Nuzzo; Stacey C Sigmon Journal: Drug Alcohol Depend Date: 2015-03-12 Impact factor: 4.492